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A B S T R A C T
Background
Alzheimer’s dementia (AD) may be caused by the formation of extracellular senile plaques comprised of beta-amyloid (Aß). In vitro and
mouse model studies have demonstrated that metal protein attenuating compounds (MPACs) promote the solubilisation and clearance
of Aß.
Objectives
To evaluate the efficacy of metal protein attenuating compounds (MPACs) for the treatment of cognitive impairment due to Alzheimer’s
dementia.
Search methods
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 29 July 2010 using the
terms: Clioquinol OR PBT1 OR PBT2 OR “metal protein” OR MPACS ORMPAC.
Selection criteria
Randomised double-blind trials in which treatment with an MPAC was administered to participants with Alzheimer’s dementia in a
parallel group comparison with placebo were included.
Data collection and analysis
Three review authors (RM, LJ, ELS) independently assessed the quality of trials according to the Cochrane Handbook for Systematic
Reviews of Interventions.
The primary outcome measure of interest was cognitive function (as measured by psychometric tests). The secondary outcome measures
of interest were in the following areas: quality of life, functional performance, effect on carer, biomarkers, safety and adverse effects,
and death.
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Main results
Two MPAC trials were identified. One trial compared clioquinol (PBT1) with placebo in 36 patients and 32 had sufficient data for
per protocol analysis. There was no statistically significant difference in cognition (as measured on the Alzheimer’s Disease Assessment
Scale - Cognition (ADAS-Cog)) between the active treatment and placebo groups at 36 weeks. The difference in mean change from
baseline ADAS-Cog score in the clioquinol arm compared with the placebo arm at weeks 24 and 36 was a difference of 7.37 (95%
confidence interval (CI) 1.51 to 13.24) and 6.36 (95% CI -0.50 to 13.23), respectively.There was no significant impact on non-
cognitive symptoms or clinical global impression. One participant in the active treatment group developed neurological symptoms
(impaired visual acuity and colour vision) which resolved on cessation of treatment and were possibly attributable to the drug.
In the second trial a successor compound, PBT2, was compared with placebo in 78 participants with mild Alzheimer’s dementia; all
were included in the intention-to-treat analysis. There was no significant difference in the Neuropsychological Test Battery (NTB)
composite or memory between placebo and PBT2 in the least squares mean change from baseline at week 12. However, two executive
function component tests of the NTB showed significant improvement over placebo in the PBT2 250 mg group from baseline to week
12: category fluency test (2.8 words, 95% CI 0.1 to 5.4; P = 0.041) and trail making part B (-48.0 s, 95% CI -83.0 to -13.0; P = 0.009).
In the executive factor Z score, the difference in least squares mean change from baseline at week 12 for PBT2 250 mg compared with
placebo was 0·27 (0·01 to 0·53; p=0·042).There was no significant effect on cognition on Mini-Mental State Examination (MMSE)
or ADAS-Cog scales. PBT2 had a favourable safety profile.
Authors’ conclusions
There is an absence of evidence as to whether clioquinol (PBT1) has any positive clinical benefit for patients with AD, or whether the
drug is safe. We have some concerns about the quality of the study methodology; there was an imbalance in treatment and control
groups after randomisation (participants in the active treatment group had a higher mean pre-morbid IQ) and the secondary analyses
of results stratified by baseline dementia severity. The planned phase III trial of PBT1 has been abandoned and this compound has been
withdrawn from development. The second trial of PBT2 was more rigorously conducted and showed that after 12 weeks this compound
appeared to be safe and well tolerated in people with mild Alzheimer’s dementia. Larger trials are now required to demonstrate cognitive
efficacy.
P L A I N L A N G U A G E S U M M A R Y
There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer’s dementia
The protein amyloid-β (Aß) is strongly implicated in the development of Alzheimer’s dementia, where it aggregates in clumps causing
damage and death of brain cells. This clumping is encouraged by copper and zinc (metal ions) in the brain. Metal protein attenuating
compounds (MPACS) bind strongly to copper and zinc (this is known as chelation), both preventing the clumping together of Aß
and promoting processes which may cause it to dissolve and so be cleared from brain cells. Therefore MPACS may be a potential
therapy for Alzheimer’s dementia. Two different types of MPAC have been used in clinical trials and the drugs are known as PBT1 and
PBT2. The trial of PBT1 compared with placebo (in 36 patients) showed no statistically significant difference in cognition or memory
between the active treatment and placebo groups at 36 weeks. We therefore conclude that there is no current evidence that treatment
with clioquinol (PBT1) has any significant effect on cognition and in particular memory (as measured by the ADAS-Cog scale) in
patients with Alzheimer’s dementia. This drug has now been withdrawn from development. The trial of PBT2 showed it was safe after
12 weeks of treatment but demonstrated no overall significant effect on cognition or memory.
B A C K G R O U N D
Alzheimer’s dementia (AD) is a progressive brain disease charac-
terised by impairment of memory andmultiple cognitive domains
(including language, praxis and executive functions). The preva-
lence of AD increases with age, affecting 4.3% of those aged 75 to
79 years and rising to 28.5% of those over 90 years (Brookmeyer
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1998). The characteristic neuropathological features are extracel-
lular senile plaques (comprised of insoluble aggregated amyloid
fibrils), intracellular neurofibrillary tangles, frequent granulovac-
uolar degeneration and loss of cortical neurons. These individual
components all occur to some extent in normal ageing. However,
the key distinction is that changes in AD are more numerous and
more widely distributed.
The amyloid hypothesis suggests that intracellular soluble
oligomers of beta-amyloid (Aß) trigger a cascade of events leading
to oxidative stress and adverse metabolic conditions within neu-
rones (Wirths 2004). The deposition of Aß plaques in the neocor-
tex occurs after this and is a key pathological finding in AD.Metals
(copper, iron and zinc) are concentrated in and around amyloid
plaques in AD brains (Atwood 2002). There is evidence that these
metals interact with Aß, catalysing the production of hydrogen
peroxide. This contributes to oxidative stress, generating Aß fibrils
that have a high tendency to aggregate, are toxic and are resistant
to clearance (Bush 1994; Bush 2003).
Metal protein attenuating compounds (MPACs) differ from tra-
ditional chelators. They have only moderate affinity for metal ions
and are capable of crossing the blood-brain barrier. Rather than
systemic binding and removal of metals from tissues, they cor-
rect abnormal metal interactions and have subtle effects on metal
homeostasis, inhibiting Zn2+ and Cu2+ induced oligermisation of
Aß. This promotes the solubilisation (and clearance) of Aß and
inhibits redox reactions that generate neurotoxic hydrogen per-
oxide. Consequently MPACs might provide a viable therapeutic
strategy for slowing or preventing the progression of Alzheimer’s
dementia (Bush 2003).
Clioquinol (5-chloro-7-iodo-8-hydroxyquinolinol) (PBT1) is an
MPAC. It is an anti-bacterial and anti-fungal agent. Topical clio-
quinol preparations are still prescribed to treat skin infections.
Clioquinol was extensively used in the past as an anti-infective,
especially for diarrhoea. It was withdrawn from oral use in 1970
after being associated with a Japanese epidemic of neurotoxicity,
subacute myelo-optic neuropathy (SMON) (Cherny 2001; Yassin
2000). This syndrome is characterised by subacute visual changes
(optic neuritis) and upper and lower motor neurone lower limb
signs. The physical signs of SMON are similar to those of suba-
cute combined degeneration of the cord secondary to vitamin B12
deficiency. It has been suggested that the Japanese population was
endemically deficient in vitamin B12, as a consequence of their
diet following the Second World War, and that this predisposed
them to SMON (Cherny 2001). Therefore, in people treated with
clioquinol SMON might be avoided by giving vitamin B12.
Clioquinol is hydrophobic and crosses the blood-brain barrier. It
binds to the Aß metal-ion complex and may act by disaggregating
collections of Aß and copper, in effect ’dissolving’ accumulations of
Aß (Bush 2003). One pilot phase II study reported no significant
effect of clioquinol versus placebo on the rate of cognitive decline
in a cohort of patients with AD (Ritchie 2003). Furthermore, the
planned phase III trial of clioquinol (PBT1) was abandoned and
this compound has been withdrawn from development (Prana
2005).
A further compound, PBT2, has been tested in a phase IIa ran-
domised, double-blind, placebo-controlled trial (Lannfelt 2008).
This MPAC is a second generation 8-OH quinoline, which in
animal models was found to target Aß oligomers (Adlard 2008).
O B J E C T I V E S
Primary objective
To evaluate the efficacy of MPACs for the treatment of cognitive
impairment due to Alzheimer’s dementia (AD).
Secondary objectives
To review the quality and quantity of research evidence available
for the treatment of ADwith MPACs. To assess any adverse effects
and the safety and tolerability of MPACs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For the analysis of treatment effects, all human, unconfounded,
randomised double-blind trials inwhich treatment with anMPAC
was administered to participants with Alzheimer’s dementia (AD)
in a parallel group comparison with placebo were included.
Types of participants
People with Alzheimer’s dementia who fulfil accepted diagnostic
criteria such as the Diagnostic and Statistical Manual of Mental
Disorders (DSM), International Classification of Diseases (ICD)
and the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related
DisordersAssociation (NINCDS-ADRDA)were evaluated (DSM
III-R; DSM-IV; McKhann 1984; WHO 1992).
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Types of interventions
This review considered studies comparing treatment with an
MPAC, or preparations inwhich anMPACwas the principle com-
ponent, by any route of administration, at any dose and for any
duration with a placebo.
Types of outcome measures
Primary outcomes
• Cognitive function (as measured by psychometric tests)
Secondary outcomes
• Clinical global impression
• Quality of life
• Functional performance
• Effect in carer
• Biomarkers
• Safety and adverse effects
• Death
Search methods for identification of studies
Electronic searches
We searched ALOIS (
www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cog-
nitive Improvement Group Specialized Register on 29 July 2010.
The search terms used were: Clioquinol OR PBT1 OR PBT2 OR
“metal protein” OR MPACS OR MPAC.
ALOIS is maintained by the Trials Search Co-ordinator of the
Cochrane Dementia Group and contains studies in the areas of
dementia prevention, dementia treatment and cognitive enhance-
ment in healthy persons. The studies are identified from the fol-
lowing.
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILIACS.
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials; the Netherlands National Trials Register, plus
others).
3. Quarterly search of the Cochrane Central Register of
Controlled Trials (CENTRAL) (The Cochrane Library).
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ‘methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
The latest search (July 2010) retrieved a total of 79 results. After
a first assessment and de-duplication of these results the authors
were left with seven references to further assess. Of these, three
were discussion or comment articles. Two articles were eligible
for inclusion in this review (Lannfelt 2008; Ritchie 2003). Two
further articles were excluded; one was a secondary analysis of data
from Lannfelt 2008 (Faux 2010) and one was an erratum related
to Lannfelt 2008. A pre-publication search was completed on 17
January 2012 and no further articles were identified.
Data collection and analysis
Selection of studies
Two review authors (RM, ES) independently examined references
retrieved by the search strategy in order to discard those which
were clearly not eligible for the review. The full text of remaining
references was retrieved and the inclusion criteria were applied to
these independently by the two review authors.
Quality assessment
Review authors (RM, LJ, ELS) independently assessed the quality
of the trials according to criteria described in the Cochrane Col-
laboration Handbook (Alderson 2004).
Data extraction
We extracted data from published reports on to a standard form
(Cochrane Dementia and Cognitive Improvement Group tem-
plate).
For each outcome with continuous data, the summary statistics
required for each trial were themean change from the baseline, the
standard error of the mean change, and the number of patients for
each treatment group at each assessment. The baseline assessment
was defined as the latest available assessment prior to randomi-
sation, no longer than two months prior. Where changes from
baseline were not reported, the mean, standard deviation and the
number of patients for each treatment group at each time point
were extracted, where available. For binary data the numbers in
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each treatment group and the numbers experiencing the outcome
of interest were sought.
For each outcome measure, data were sought on every patient
randomised. To allow an intention-to-treat analysis, the data were
sought irrespective of compliance, whether or not the patient was
subsequently deemed ineligible or otherwise excluded from treat-
ment or follow-up. If intention-to-treat data were not available in
the publications, the data of those who completed the trial or who
were treated throughout according to the protocol (’per protocol’)
were sought and indicated as such.
Data analysis
The outcomes measured in clinical trials of dementia and cogni-
tive impairment often arise from ordinal rating scales. Where the
rating scales used in the trials had a reasonably large number of
categories (more than 10) the data were treated as continuous out-
comes arising from a normal distribution. Summary ’change from
baseline’ statistics (n, mean and standard deviation) were sought
for each rating scale at each assessment time, for each treatment
group, and in each trial.
When change from baseline results were not reported, we calcu-
lated the required summary statistics from the group means and
standard deviations at baseline and assessment time. In such cases,
we assumed a zero correlation between the measurements at base-
line and assessment time. This conservative method overestimates
the standard deviation of the change from baseline but is prefer-
able in a meta-analysis.
For continuous outcomes, overall estimates of the treatment dif-
ferences between the intervention and placebo would have been
calculated as the weighted average of the individual study estimates
if there had been more than one study.
For binary outcomes, such as clinical improvement or no clinical
improvement, we used the odds ratio to measure treatment effect.
If there had been more than one study, we would have calculated
a weighted estimate of the typical treatment effect across trials.
Overall estimates of the treatment difference were presented.
R E S U L T S
Description of studies
Two trials were included, Ritchie 2003 compared clioquinol
(PBT1) with placebo and Lannfelt 2008 compared PBT2 to
placebo.
In the first randomised double-blind, placebo-controlled trial (
Ritchie 2003), clioquinol (PBT1) was started at a dose of 125 mg
twice a day for the first 12 weeks, increased to 250 mg twice daily
from weeks 13 to 24, and 375 mg twice daily from weeks 25 to
36. The total duration of randomised treatment was 36 weeks.
A total of 36 people were recruited whomet the protocol criteria of
having a diagnosis of probable AD using NINCDS-ADRDA, an
ADAS-Cog score of 20 to 45, an MMSE score of between 10 and
24 and having been on donepezil 5 to 10 mg for over six months.
Themean age of participants was 73 years. In the clioquinol group
50% were male compared with 56% in the placebo group. The
mean baseline ADAS-Cog scores were 25.56 and 27.06 in the
clioquinol and placebo groups, respectively. The clioquinol and
placebo groups did not differ across most demographic, biological
and clinical variables at baseline, however the treatment arm had a
higher mean pre-morbid IQ than the placebo group as estimated
using the National Adult Reading Test (111.4 versus 104.9; t30df
= 2.27; P = 0.03) and a lower level of thyrotropin (1.14 versus 2.00
mIU/L; t30df = 4.40; P < 0.001). For other details of the trial, see
the ’Characteristics of included studies’ table. Additional datawere
collected on plasma zinc, copper and Aß levels at four-weekly in-
tervals throughout the study. Further studies of clioquinol (PBT1)
were abandoned in favour of a successor compound, PBT2 (Prana
2005).
In the second randomised double-blind, placebo-controlled trial
included in this review (Lannfelt 2008), a total of 78 participants
were randomised after meeting the entry criteria: an ADAS-Cog
score of 10 to 25 and a MMSE score of between 20 and 26 (both
scores must have been consistent with early AD), were taking a sta-
ble dose of acetylcholinesterase inhibitor for at least four months,
and met the NINCDS-ADRDA criteria for Alzheimer’s demen-
tia. Patients were assigned to receive PBT2 (50 mg or 250 mg) or
placebo once per day for 12 weeks. The three groups did not differ
in terms of demographic characteristics at baseline. The mean age
of the study population was 72 years and the baseline ADAS-cog
scores were 18.9 in the placebo group and PBT2 50 mg group
and 18.7 in the group who received 250 mg of PBT2. For fur-
ther details see the table ’Characteristics of included studies’. The
principle outcomes were safety and tolerability; the secondary out-
comes were cognition and effects on cerebrospinal fluid (CSF) and
plasma biomarkers.
Scales
Alzheimer’s Disease Assessment Scale-cognitive section
(ADAS-Cog) (Rosen 1984)
ADAS was designed to measure the severity of the most important
symptoms of AD. Its subscale ADAS-Cog is a standard measure to
assess change in cognitive function in clinical trials. It consists of
11 tasks measuring the disturbances of memory, language, praxis,
attention and other cognitive abilities, which are often referred to
as the core symptoms of AD. It is a 70-point scale and patients are
given a score on 11 sub-items ranging from 0 to 5, with higher
scores suggesting greater impairment.
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Alzheimer’s Disease Assessment Scale-non cognitive
section (ADAS-NC) (Rosen 1984)
ADAS was designed to measure the severity of the most impor-
tant symptoms of AD. This subscale, ADAS-NC, was designed to
assess the non-cognitive behavioral dysfunctions characteristic of
persons with Alzheimer’s dementia. It consists of 10 items and ex-
aminesmoods and behaviours including delusions, hallucinations,
changes in appetite and motor behaviours. Scores on each sub-
item range from 0 to 5, total scores may range from 0 to 50, and
higher scores suggest greater behavioural or mood disturbances.
Clinician’s Interview-Based Impression of Change+
(CIBIC+) (Knopman 1994)
This is a semi-structured interview performedwith the caregiver. It
consists of a 7-point Likert scale that assesses change from baseline
in terms of the clinician’s rating of global function. The scale ranges
from 1 (’very much improved’) to 7 (’very much worse’), with 4
indicating no change since baseline.
The Neuropsychological Test Battery (NTB) (Harrison
2007)
TheNTBgives nine outcomemeasures, four ofmemory:Wechsler
Memory Scale Verbal Paired Associates test (immediate and de-
layed) and the Rey Auditory Verbal Learning Test (immediate and
delayed); and five of executive function: Wechsler Memory Digit
Span, Controlled Oral Word Association Test, Category Fluency
Test and trail making test parts A and B. It has been shown to be
reliable to assess changes in patients with mild AD. Data can be
analysed at the level of individual item scores, domain scores with
comparison of the z-statistic or by a composite (global) score.
Mini-mental State Examination (MMSE) (Folstein
1975)
TheMMSE evaluates cognition in five areas: orientation, immedi-
ate recall, attention and calculation, delayed recall, and language.
The scores range from 0 (severe impairment) to 30 (normal).
Risk of bias in included studies
The study of Ritchie 2003 was a double-blind, placebo-controlled,
parallel-group randomised design. The statistical analysis was un-
dertaken by independent contractors. The study was reported as
a phase 2 pilot clinical trial and there were a number of method-
ological limitations which must be considered.
The report did not detail the measures taken to implement and
protect double-blinding or contain information regarding the
method of randomisation or concealment of the treatment al-
location (this may have been due to lack of space in the pub-
lished report). Twenty-nine patients failed the screening; five due
to their cognition being too poor, 15 because their cognition was
too good, five due to ill health: and four failed the neurological
screen. In total, five participants were withdrawn after randomisa-
tion, two from the placebo group and three from the active treat-
ment arm. The reasons for withdrawal are described briefly in the
study flowchart. The treatment arm had higher mean pre-morbid
IQ than the placebo group and a lower level of thyrotropin sug-
gesting an imbalance post-randomisation.
In addition to the stated primary efficacy measure (ADAS-Cog),
data were collected on plasma zinc, copper and Aß levels at four-
weekly intervals. The discussion and title of the study, however,
suggested that the main aim of the study was ’proof of concept’
that clioquinol targets Aß metabolism. Despite this, the study
was only powered to detect “conspicuous effects” on cognition,
thus the interpretation of the results of additional analyses on the
effect of clioquinol on plasma zinc, copper and Aß levels should be
interpreted with caution. No details of the power calculation were
given. As well as analysing the difference in change from baseline
between treatment arms, a secondary analysis was performed and
the groups stratified by severity. The report explained that this was
a ’planned’ analysis although this was not stated as being a primary
aim of the study. The stratification resulted in small numbers of
participants in each group for subsequent analyses (less severely
affected group: placebo n = 7, active treatment n = 8; more severely
affected group: placebo n = 9, active treatment = 8).
The study of Lannfelt 2008 was also a double-blind, placebo-con-
trolled, parallel-group randomised design. The statistical analysis
was conducted by the study team. Eighty-eight potential study
participants were assessed for eligibility and 78 were recruited as
theymet baseline criteria. Safetymeasures, plasma biomarkers and
cognition on the NTB were assessed at baseline and at weeks 2,
4, 8, and 12 with a follow-up at week 14. ADAS-Cog and the
MMSE were done at screening and at week 12.
Placebo capsules were identical to the PBT2 capsules and the ran-
domisation was conducted by an independent statistician using
a computerised random number generator. Patients, carers, study
staff and the sponsor were blinded to treatment allocation. Ten
individuals failed the initial screening because they did not meet
inclusion criteria and a further four participants were withdrawn
post-randomisation (one did not meet eligibility criteria, one for
taking excluded medication, one due to carer illness, and one due
to non-compliance). The authors clearly stated that this was an
exploratory study and therefore there was no formal calculation
of sample size. Safety and efficacy analyses were done on an inten-
tion-to-treat basis. The primary objective was to study safety and
tolerability.
Effects of interventions
PBT1 (clioquinol)
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There was one included trial (Ritchie 2003) of clioquinol com-
pared with placebo. Thirty-six patients were recruited and 32 had
sufficient data for per protocol analysis.
Primary outcome
ADAS-Cog
The primary outcome, ADAS-Cog, was subject to two-way anal-
ysis of variance with factors of treatment arm. Both the clioquinol
and placebo arms showed a decrease (improvement) inADAS-Cog
scores at weeks 24 and 36, a difference in mean change from base-
line of 7.37 (95% confidence interval (CI) 1.51 to 13.24) in the
clioquinol arm and 6.36 (95% CI -0.50 to 13.23) in the placebo
arm. However, the main effect of the treatment arm was not sig-
nificant at any time point during the study. The effect of severity
of illness was measured by stratification of the sample (using a cut-
point of the median): ADAS-Cog < 25 (less severely affected) and
ADAS-cog > 25 (more severely affected). This analysis was not
pre-specified in the protocol. Significant differences favouring the
clioquinol arm were found only at weeks 4 (F1,28 = 7.73; P =
0.01) and 24 ( F1,28 = 6.63; P = 0.02) on post hoc analysis in
the more severely affected patients. Therefore, this may have been
a chance finding attributable to multiple comparisons at multiple
time points.
Secondary outcomes
MMSE
The authors stated that analysis of MME scores showed a similar
pattern to the ADAS-Cog but no further details were given in the
paper.
ADAS-Non cog
Analysis of these results showed no statistically significant differ-
ence between the two groups.
CIBIC
Analysis of these results showed no statistically significant differ-
ence in global function between the two groups.
Plasma biomarkers (Aß42, zinc and copper)
The authors stated that the plasma Aß42 level declined signifi-
cantly frombaseline in the clioquinol group fromweek20onwards
(actual figures for plasma Aß42 not given). This was the opposite
for the placebo group, which showed a rise in plasma Aß42 level
during the same time period. We do not know what the clinical
effect of this was. The total plasma zinc level was described as ’in-
creased’ in the clioquinol group at 32 weeks compared to placebo.
There was no effect on plasma copper levels. Again, as with the
changes noted in plasma Aß42 levels, the underlying mechanisms
and clinical implications of this are not known.
Safety and tolerability
As there is an association of clioquinol with subacute myelopathic
neuropathy (SMON), neurological adverse events were of interest.
There were a total of 123 attributable adverse events reported, 64
in the treatment group and 59 in the placebo arm. Serious adverse
events occurred in two of 16 patients in the treatment group. A 66
year-old woman with a background history of hypertension, hy-
perlipidaemia, glaucoma and visual migraine developed impaired
visual acuity and colour vision in the absence of other neurological
signs or symptoms. She was on a dose of 375 mg of clioquinol
twice a day. The symptoms resolved on treatment cessation and
were thought to be possibly attributable to the drug. Another pa-
tient in the treatment arm reported syncope due to impaired car-
diac function. Serious adverse events also occurred in three of the
16 in the placebo arm, one death due to intracranial haemorrhage,
three hospitalisations due to hip pain and one due to confusion.
PBT2
There was one included trial (Lannfelt 2008) of PBT2 at doses
of 50 mg or 250 mg compared with placebo. Of the 78 patients
randomised, all were included in the intention-to-treat analysis.
Primary outcome
Neuropsychological test battery (NTB)
There was no significant difference in the NTB composite, mem-
ory or executive scores between placebo and PBT2 in the least
squares mean change from baseline at week 12. However, two ex-
ecutive function component tests of the NTB showed significant
improvement over placebo in the PBT2 250 mg group from base-
line to week 12: category fluency test (2.8 words, 95% CI 0.1 to
5.4; P = 0.041) and trail making part B (-48.0 s, 95% CI -83.0
to -13.0; P = 0.009). It should be noted that subsequently an er-
ratum was published describing an error in the reporting of the
composite and executive function z-scores for the NTB (Lannfelt
2008 (erratum)). There remained no significant difference in the
NTB composite scores between placebo and PBT2 in the least
squares mean change from baseline at week 12. In the executive
factor Z score, the difference in least squares mean change from
baseline at week 12 for PBT2 50 mg compared with placebo was
0·18 (−0·06 to 0·42; p=0·137) and for PBT2 250 mg compared
with placebo was 0·27 (0·01 to 0·53; p=0·042).
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A further post hoc analysis of this data (Faux 2010) found that
the proportions of patients showing improvement on NTB Com-
posite or Executive Factor z-scores were significantly greater in the
PBT2 250 mg group than in the placebo group. There were no
correlations between changes in cerebrospinal fluid (CSF) amy-
loid-ß or tau species and cognitive changes.
MMSE
After 12 weeks there was no significant improvement in MMSE
scores in either the PBT 50 mg or 250 mg groups compared to
placebo.
ADAS-Cog
After 12 weeks there was no significant improvement in ADAS-
Cog scores in either the PBT 50 mg or 250 mg groups compared
to placebo.
Secondary outcomes
Safety and tolerability
Forty-two (54%) patients had at least one treatment emergent ad-
verse event (10 (50%) on PBT2 50 mg, 18 (62%) on PBT2 250
mg, and 14 (48%) on placebo). The most common adverse events
in the whole study sample were headache, dizziness, somnolence,
nasopharyngitis and fatigue. Two patients in the placebo group ex-
perienced a serious adverse event (one man had urosepsis and one
woman a transient Ischaemic attack). No serious adverse events
were reported by patients on PBT2. There were no clinically sig-
nificant adverse findings on vital signs, biochemical, haematolog-
ical, urinalysis, neurological, opthalmological, electrocardiograph
(ECG) or physical parameters.
Plasma biomarkers (Aß42, Aß40, zinc and copper)
PBT2 had no significant effect on plasma concentrations of Aß42,
Aß40, zinc and copper.
CSF biomarkers (Aß42, Aß40, total tau, phosphorylated tau,
zinc and copper)
Patients treated with PBT2 250 mg had a dose-dependent (P
= 0.023) and significant reduction in CSF Aß42 concentration
compared with those treated with placebo: the difference in least
squares mean change from baseline was -56.0 pg/mL (95% CI -
101.5 to -11.0; P = 0.006). PBT2 had no significant effect on CSF
Aß40, total tau, phosphorylated tau, zinc or copper.
D I S C U S S I O N
At the beginning of this review we outlined the physiological rea-
sons why MPACs may be useful in the treatment of AD and set
out to look for evidence of efficacy to support this. We identi-
fied two randomised placebo controlled trials of MPACs. The
first (Ritchie 2003) compared the MPAC clioquinol (PBT1) with
placebo. There were no significant difference on the primary out-
come measure (cognition) between clioquinol and placebo, or on
the secondary outcomes of non-cognitive symptoms (ADAS-NC)
or clinical global impression (Clinician’s Interview-Based Impres-
sion of Change (CIBIC)). We have concerns about the quality of
the reporting of the study, in particular the lack of information
on randomisation and concealment of treatment allocation. The
stratification of the analysis by baseline dementia severity only
serves to suggest pre-specified analyses in future studies and is not,
at this stage, of clinical relevance. The significant differences be-
tween some of the baseline variables highlight the importance of
adequate sample size and randomisation, and the risks that such
differences canundermine or cause real differences in the outcomes
of interest. The study was conducted over 36 weeks; this may not
be sufficient time to detect clinically meaningful end points, evi-
dence of modification of the disease course or longer-term adverse
events.
The phase IIa trial of a second MPAC (Lannfelt 2008), PBT2,
was more rigorous with regards to randomisation, allocation and
reporting and analysis of results. The primary outcome was safety
and tolerability and the results of this were favourable. Cognition
was a secondary outcome and PBT2 did not have a statistically
significant effect on ADAS-Cog or MMSE scores, although there
was a statistically significant improvement in the executive factor
Z score in those treated with the higher dose of PBT2 (250mg).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Clioquinol PBT1 cannot be recommended for clinical use. There
is no current evidence for clinical efficacy and the one small study
detailed in this review does not include enough participants to
draw any conclusions on safety. In a 12 week trial PBT2 appeared
to have a favourable safety profile. We do not yet know whether
the effects of PBT2 on cognition and biomarkers have clinical
significance.
Implications for research
MPACs potentially offer a novel approach to the treatment of
Alzheimer’s dementia. In vitro and animal studies suggest they
promote the solubilisation and clearance of Aß. The clioquinol
PBT1 trial did not demonstrate efficacy. However, this phase II
trial may have been underpowered to detect an effect on cognition.
The results of the phase IIa trial of PBT2 suggest that future, larger
phase III trials of longer duration are warranted to demonstrate
whether PBT2 has disease modifying effects. In addition to cog-
nition, these should consider other clinically relevant outcomes
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such as non-cognitive behavioural symptoms and clinical global
impression. It is important that concerns about neurological side
effects of MPACs are balanced with the need to urgently find ther-
apies for Alzheimer’s dementia, a progressive neurodegenerative
disease for which currently no disease modifying agents are avail-
able.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Lannfelt 2008
Methods Allocation: randomisation
Blindness: double blind
Duration: 12 weeks
Participants Diagnosis: Early Alzheimer’s dementia. N=78
Age: Mean 72, range 58-83 years
Sex: F39, M39
Setting: Multicentre (Sweden 8 centres, Australia 7 centres)
Inclusion: NINCDS-ADRDA criteria for Alzheimer’s dementia, Adas-Cog score of 10-
25, MMSE score of between 20 and 26, taking a stable dose of acetylcholinesterase
inhibitor for at least 4 months, modified Hachinski score of 4 points or less, CT or MRI
scan consistent with Alzheimer’s dementia
Interventions PBT2 (50mg or 250mg) or placebo once per day for 12 weeks
Outcomes Primary outcome: safety and tolerability
Secondary outcomes: NTB at baseline, 2,4,8,12 and 14 weeks
Adas-Cog and MMSE at baseline and 12 weeks
Notes Plasma biomarkers (Aβ42, Aβ40, zinc and copper, baseline, 2,4,8,12 and 14 weeks).
CSF biomarkers (Aβ42, Aβ40, total tau, phosphorylated tau, zinc and copper, baseline
and week 12)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer random number
generation
Allocation concealment (selection bias) Low risk Placebo capsules were identical to PBT2
capsules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study is described as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study is described as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used intention-to-treat analysis
11Metal protein attenuating compounds for the treatment of Alzheimer’s dementia (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lannfelt 2008 (Continued)
Selective reporting (reporting bias) High risk Selection and reporting of individual items
from a test battery
Ritchie 2003
Methods Allocation: randomisation
Blindness: double blind
Duration: 36 weeks
Participants Diagnosis: Alzheimer’s dementia. N=36
Age: Mean 72.5, SD 8.4, range 56-87 years
Sex: F 15, M 17
Setting:Australia
Inclusion: diagnosis of probable AD using NINCDS-ADRDA, an ADAS-Cog score of
20-45, an MMSE score of between 10-24 and having been on donepezil 5-10 mg for
over six months
Interventions Clioquinol started at 125 mg twice daily from weeks 1 to 12, 250 mg daily from weeks
13 to 24, and 375 mg twice daily from weeks 25 to 36
Outcomes Primary outcome: change from the baseline ADAS-Cog at weeks 4, 12, 24 and 36
Secondary outcomes: ADAS-NC, MMSE, CIBIC Plasma Aß, zinc and copper levels
Notes Plasma Aß, zinc, and copper levels were measured every 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details not given in the paper
Allocation concealment (selection bias) Unclear risk Details not given in the paper
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study is described as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study is described as double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information given on subjects who did
not complete the trial
Selective reporting (reporting bias) High risk Subjects were stratified by “severity” for sec-
ondary analyses
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Finefrock 2003 Not a clinical trial
Mastwyk 2003 Not a clinical trial
Regland 2001 Randomised controlled trial but not placebo controlled
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D A T A A N D A N A L Y S E S
Comparison 1. Change ADAS-Cog after 36 weeks clioquinol or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in ADASCog at 36
weeks
1 32 Mean Difference (IV, Fixed, 95% CI) -2.67 [-11.60, 6.26]
Analysis 1.1. Comparison 1 Change ADAS-Cog after 36 weeks clioquinol or placebo, Outcome 1 Change in
ADASCog at 36 weeks.
Review: Metal protein attenuating compounds for the treatment of Alzheimer’s dementia
Comparison: 1 Change ADAS-Cog after 36 weeks clioquinol or placebo
Outcome: 1 Change in ADASCog at 36 weeks
Study or subgroup Clioquinol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ritchie 2003 16 4.33 (12.89) 16 7 (12.89) 100.0 % -2.67 [ -11.60, 6.26 ]
Total (95% CI) 16 16 100.0 % -2.67 [ -11.60, 6.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Clioquinol Favours placebo
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A P P E N D I C E S
Appendix 1. Update search: July 2010
Source Search strategy Hits
MEDLINE (Ovid SP) 1. exp Dementia/
2. Delirium/
3. Wernicke Encephalopathy/
4. Delirium, Dementia, Amnestic, Cogni-
tive Disorders/
5. dement*.mp.
6. alzheimer*.mp.
7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. (“organic brain disease” or “organic
brain syndrome”).mp
11. (“normal pressure hydrocephalus” and
“shunt*”).mp.
12. “benign senescent forgetfulness”.mp.
13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.
16. (creutzfeldt or jcd or cjd).mp.
17. huntington*.mp.
18. binswanger*.mp.
19. korsako*.mp.
20. or/1-19
21. Clioquinol/
22. MPAC*.ti,ab.
23. PBT*.ti,ab.
24. “metal protein attenuat*”.ti,ab.
25. clioquinol*.ti,ab.
26. or/21-25
27. 20 and 26
28. (2009* or 2010*).ed.
29. 27 and 28
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomized.ab.
33. placebo.ab.
34. randomly.ab.
35. trial.ab.
36. groups.ab.
37. or/30-36
38. (animals not (humans and animals)).
sh.
39. 37 not 38
40. 29 and 39
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(Continued)
EMBASE (Ovid SP) 1. exp dementia/
2. Lewy body/
3. delirium/
4. Wernicke encephalopathy/
5. cognitive defect/
6. dement*.mp.
7. alzheimer*.mp.
8. (lewy* adj2 bod*).mp.
9. deliri*.mp.
10. (chronic adj2 cerebrovascular).mp.
11. (“organic brain disease” or “organic
brain syndrome”).mp
12. “supranuclear palsy”.mp.
13. (“normal pressure hydrocephalus” and
“shunt*”).mp.
14. “benign senescent forgetfulness”.mp.
15. (cerebr* adj2 deteriorat*).mp.
16. (cerebral* adj2 insufficient*).mp.
17. (pick* adj2 disease).mp.
18. (creutzfeldt or jcd or cjd).mp.
19. huntington*.mp.
20. binswanger*.mp.
21. korsako*.mp.
22. CADASIL.mp.
23. or/1-22
24. clioquinol/
25. MPAC*.ti,ab.
26. PBT*.ti,ab.
27. “metal protein attenuat*”.ti,ab.
28. clioquinol*.ti,ab.
29. or/24-28
30. 23 and 29
31. (2009* or 2010*).em.
32. 30 and 31
33. randomized controlled trial/
34. controlled clinical trial/
35. randomi?ed.ab.
36. placebo.ab.
37. randomly.ab.
38. trial.ab.
39. groups.ab.
40. or/33-39
41. 32 and 40
PsycINFO (OVID SP) 1. exp Dementia/
2. exp Delirium/
3. exp Huntingtons Disease/
4. exp Kluver Bucy Syndrome/
5. exp Wernickes Syndrome/
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(Continued)
6. exp Cognitive Impairment/
7. dement*.mp.
8. alzheimer*.mp.
9. (lewy* adj2 bod*).mp.
10. deliri*.mp.
11. (chronic adj2 cerebrovascular).mp.
12. (“organic brain disease” or “organic
brain syndrome”).mp
13. “supranuclear palsy”.mp.
14. (“normal pressure hydrocephalus” and
“shunt*”).mp.
15. “benign senescent forgetfulness”.mp.
16. (cerebr* adj2 deteriorat*).mp.
17. (cerebral* adj2 insufficient*).mp.
18. (pick* adj2 disease).mp.
19. (creutzfeldt or jcd or cjd).mp.
20. huntington*.mp.
21. binswanger*.mp.
22. korsako*.mp.
23. (“parkinson* disease dementia” or PDD
or “parkinson* dementia”).mp
24. or/1-23
25. clioquinol*.mp.
26. MPAC*.ti,ab.
27. PBT*.ti,ab.
28. “metal protein attenuat*”.ti,ab.
29. or/25-28
30. 24 and 29
31. (2009* or 2010*).up.
32. 30 and 31
CINAHL (EBSCOhost) S1 (MH “Dementia+”)
S2 (MH “Delirium”) or (MH “Delir-
ium, Dementia, Amnestic, Cognitive Dis-
orders”)
S3 (MH “Wernicke’s Encephalopathy”)
S4 TX dement*
S5 TX alzheimer*
S6 TX lewy* N2 bod*
S7 TX deliri*
S8 TX chronic N2 cerebrovascular
S9 TX “organic brain disease” or “organic
brain syndrome”
S10 TX “normal pressure hydrocephalus”
and “shunt*”
S11 TX “benign senescent forgetfulness”
S12 TX cerebr* N2 deteriorat*
S13 TX cerebral* N2 insufficient*
S14 TX pick* N2 disease
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(Continued)
S15 TX creutzfeldt or jcd or cjd
S16 TX huntington*
S17 TX binswanger*
S18 TX korsako*
S19 S1 or S2 or S3 or S4 or S5 or S6 or S7
or S8 or S9 or S10 or S11 or S12 or S13 or
S14 or S15 or S16 or S17 or S18
S20 TX clioquinol
S21 MPAC*
S22 PBT*
S23 TX “metal protein attenuat*”
S24 S20 or S21 or S22 or S23
S25 S19 and S24
CENTRAL (The Cochrane Library) #1 MeSH descriptor Dementia explode all
trees
#2 MeSH descriptor Delirium, this term
only
#3 MeSH descriptor Wernicke En-
cephalopathy, this term only
#4 MeSH descriptor Delirium, Dementia,
Amnestic, Cognitive Disorders, this term
only
#5 dement*
#6 alzheimer*
#7 “lewy* bod*”
#8 deliri*
#9 “chronic cerebrovascular”
#10 “organic brain disease” or “organic
brain syndrome”
#11 “normal pressure hydrocephalus” and
“shunt*”
#12 “benign senescent forgetfulness”
#13 “cerebr* deteriorat*”
#14 “cerebral* insufficient*”
#15 “pick* disease”
#16 creutzfeldt or jcd or cjd
#17 huntington*
#18 binswanger*
#19 korsako*
#20 (#1 OR #2 OR #3 OR #4 OR #5 OR
#6 OR #7 OR #8 OR #9 OR #10 OR #
11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19)
#21 clioquinol OR PBT1 OR PBT2 OR
“metal protein*”
#22 (#20 AND #21)
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(Continued)
ALOIS (www.medicine.ox.ac.uk/alois) Keyword search: ClioquinolORPBT1OR
PBT2 OR “metal protein” OR MPACS
OR MPAC
ClinicalTrials.gov (Clioquinol OR PBT1 OR PBT2 OR
metal protein) AND (Alzheimer OR
alzheimers OR alzheimer’s OR dementia)
ICTRP (The WHO portal) Clioquinol ORPBT1ORPBT2ORmetal
protein
LILACS (BIREME) clioquinol AND OR AND PBT1 AND
OR AND PBT2 AND OR AND “metal
AND protein$” AND OR ANDMPAC$
Web of Science and Conference Proceed-
ings (Web of Knowledge)
Topic=(Clioquinol
OR PBT1 OR PBT2 OR “metal protein”)
AND Topic=(alzheimer* OR dement*)
Timespan=2009-2010. Databases=SCI-
EXPANDED, SSCI, CPCI-S
WH A T ’ S N E W
Last assessed as up-to-date: 9 February 2012.
Date Event Description
20 February 2014 New citation required but conclusions have not
changed
Abstract amended to reflect correctionof Lannfelt 2008
trial data
20 February 2014 Amended Abstract amended
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2006
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Date Event Description
5 September 2012 Amended Correction of Lannfelt 2008 trial data
9 February 2012 New citation required and conclusions have changed Review updated February 2012
9 February 2012 New citation required and conclusions have changed Update June 2007
The literature search undertaken in May 2005 was up-
dated in February 2007. Since the original Cochrane
review was published in 2006, Prana Biotechnology has
suspended PBT1 development.
PBT2, a successor compound to PBT1 for Alzheimer’s
disease began a Phase I human clinical trial in March
2005. Data from this trial were published in 2008 and
these have been included in this review
5 November 2008 Amended Converted to new review format.
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S O U R C E S O F S U P P O R T
Internal sources
• Oxfordshire Mental Healthcare Trust, UK.
• Barnet Enfield and Haringey Mental Health Trust, UK.
• Mental Health Sciences Unit, University College London, UK.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Alzheimer Disease [∗drug therapy]; Amyloid beta-Peptides [metabolism]; Chelating Agents [adverse effects; ∗therapeutic use]; Clio-
quinol [adverse effects; analogs & derivatives; ∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Aged; Humans
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